
DNLI
Denali Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.805
Open
13.750
VWAP
--
Vol
1.56M
Mkt Cap
1.98B
Low
13.520
Amount
--
EV/EBITDA(TTM)
--
Total Shares
142.61M
EV
1.16B
EV/OCF(TTM)
--
P/S(TTM)
--
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.735
+24.65%
--
--
-0.771
+22.38%
--
--
-0.767
+14.48%
Estimates Revision
The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -27.72% over the past three months. During the same period, the stock price has changed by -18.26%.
Revenue Estimates for FY2025
Revise Downward

-27.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+5.9%
In Past 3 Month
Stock Price
Go Down

-18.26%
In Past 3 Month
11 Analyst Rating

138.35% Upside
Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 32.44 USD with a low forecast of 27.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy

138.35% Upside
Current: 13.610

Low
27.00
Averages
32.44
High
40.00

138.35% Upside
Current: 13.610

Low
27.00
Averages
32.44
High
40.00
BofA
Tazeen Ahmad
Buy
downgrade
$28 -> $27
2025-05-19
Reason
BofA
Tazeen Ahmad
Price Target
$28 -> $27
2025-05-19
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi' as it expects a launch in early 2026, the analyst noted.
Baird
Outperform -> NULL
downgrade
$30 -> $29
2025-05-08
Reason
Baird
Price Target
$30 -> $29
2025-05-08
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Denali Therapeutics to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.
B. Riley
Mayank Mamtani
Buy
downgrade
$35 -> $30
2025-05-08
Reason
B. Riley
Mayank Mamtani
Price Target
$35 -> $30
2025-05-08
downgrade
Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Denali Therapeutics to $30 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm updated the company's model. FDA-related uncertainty continues to weigh on the stock, but attainment of regulatory and pipeline execution milestones in coming months, alongside visibility into new FDA leadership staff taking form, could bode well for Denali, the analyst tells investors in a research note.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$30 → $28
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$30 → $28
2025-03-10
Maintains
Strong Buy
Reason
Morgan Stanley
Matthew Harrison
Buy
Initiates
$41 → $33
2025-03-07
Reason
Morgan Stanley
Matthew Harrison
Price Target
$41 → $33
2025-03-07
Initiates
Buy
Reason
Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics with an Overweight rating and a price target of $33, down from $41. The firm views Denali as "a key beneficiary" in an evolving landscape following FDA recognition of elevated heparan sulfate as a surrogate endpoint and models $359M in unadjusted sales for Tividenofusp Alfa in Hunter disease and $646M in unadjusted sales for DNL126 for Sanfilippo disease.
B. Riley Securities
Mayank Mamtani
Strong Buy
Reiterates
$38 → $35
2025-03-05
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$38 → $35
2025-03-05
Reiterates
Strong Buy
Reason
B. Riley lowered the firm's price target on Denali Therapeutics to $35 from $38 and keeps a Buy rating on the shares following the Q4 report. The company highlighted key corporate priorities aimed at de-risking the path to U.S. FDA approvals for multiple programs within its Enzyme Transport Vehicle franchise, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -4.46, compared to its 5-year average forward P/E of -13.35. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-13.35
Current PE
-4.46
Overvalued PE
-0.36
Undervalued PE
-26.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-10.75
Current EV/EBITDA
-2.09
Overvalued EV/EBITDA
-1.11
Undervalued EV/EBITDA
-20.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
61.75
Current PS
76.84
Overvalued PS
102.09
Undervalued PS
21.40
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+10.08%
-145.58M
Operating Profit
FY2025Q1
YoY :
+30.62%
-132.97M
Net Income after Tax
FY2025Q1
YoY :
+14.71%
-0.78
EPS - Diluted
FY2025Q1
YoY :
+17.95%
-136.55M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
0-3
Months
7.4M
USD
1
3-6
Months
0.0
USD
0
6-9
Months
2.0M
USD
10
0-12
Months
2.1M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
326.3K
Volume
1
3-6
Months
1,000K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
135.0K
Volume
Months
6-9
1
250.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
0-3
Months
7.4M
USD
1
3-6
Months
0.0
USD
0
6-9
Months
2.0M
USD
10
0-12
Months
2.1M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DNLI News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
08:23:22
Royalty Pharma appoints Ho, Weatherman to board of directors

2025-07-07 (ET)
2025-07-07
10:54:26
Denali noted no FDA panel meeting in call with William Blair

2025-07-07
08:02:22
Denali announces FDA acceptance, priority review for tividenofusp alfa BLA

Sign Up For More Events
Sign Up For More Events
News
5.0
07-17Yahoo FinanceRoyalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
3.0
07-10NASDAQ.COMLABU's Holdings Imply 58% Gain Potential
9.0
07-07NASDAQ.COMDenali: FDA To Review BLA Seeking Accelerated Approval For Tividenofusp Alfa
Sign Up For More News
People Also Watch

VCYT
Veracyte Inc
24.470
USD
-2.20%

POWL
Powell Industries Inc
233.320
USD
-3.75%

FHI
Federated Hermes Inc
49.340
USD
+0.98%

WDFC
WD-40 Co
213.840
USD
+1.46%

TRN
Trinity Industries Inc
25.290
USD
-3.84%

TEX
Terex Corp
50.340
USD
-2.48%

OUT
OUTFRONT Media Inc
17.730
USD
-1.01%

SXT
Sensient Technologies Corp
111.400
USD
-1.35%

NHI
National Health Investors Inc
71.330
USD
+1.97%
FAQ

What is Denali Therapeutics Inc (DNLI) stock price today?
The current price of DNLI is 13.61 USD — it has decreased -0.15 % in the last trading day.

What is Denali Therapeutics Inc (DNLI)'s business?

What is the price predicton of DNLI Stock?

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Denali Therapeutics Inc (DNLI)'s fundamentals?

How many employees does Denali Therapeutics Inc (DNLI). have?
